TABLE 4.
Significance analysis of the characteristics of ADRS in severe ADRs.
| Name | Option | ADRS | Total | Inspection method | χ2 | P | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hematologic | Mucocutaneous system | Digestive system | Systemic damage | Respiratory | Cardiovascular system | Other | ||||||
| Age | <18 | 110 | 10 | 6 | 0 | 6 | 0 | 7 | 139 | pearsonchi-square test | 106.246 | 0.000*** |
| 19∼45 | 12 | 10 | 9 | 2 | 3 | 2 | 2 | 40 | ||||
| 46∼65 | 61 | 36 | 15 | 15 | 6 | 8 | 9 | 150 | ||||
| 66∼79 | 31 | 20 | 1 | 3 | 1 | 2 | 5 | 63 | ||||
| >80 | 3 | 5 | 0 | 1 | 1 | 1 | 5 | 16 | ||||
| Sex | Male | 66 | 36 | 14 | 1 | 2 | 5 | 12 | 136 | pearsonchi-square test | 19.853 | 0.003*** |
| Female | 151 | 45 | 17 | 20 | 15 | 8 | 16 | 272 | ||||
| Classes of drugs | Anti-tumor | 201 | 4 | 18 | 5 | 4 | 0 | 6 | 238 | pearsonchi-square test | 366.906 | 0.000*** |
| Anti-infectious agent | 4 | 31 | 2 | 2 | 1 | 0 | 2 | 42 | ||||
| Circulating system drugs | 2 | 3 | 4 | 0 | 2 | 4 | 2 | 17 | ||||
| Respiratory drugs | 1 | 12 | 0 | 0 | 1 | 3 | 1 | 18 | ||||
| Blood system drugs | 1 | 1 | 3 | 1 | 0 | 0 | 3 | 9 | ||||
| Other | 8 | 30 | 4 | 13 | 9 | 6 | 14 | 84 | ||||
* * *, * * *, and * represent 1%, 5%, and 10% significance levels, respectively.